International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.
Trappe RU, Choquet S, Dierickx D, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Tarella C, Shpilberg O, Sender M, Salles G, Morschhauser F, Jaccard A, Lamy T, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Leithäuser M, Schlattmann P, Anagnostopoulos I, Raphael M, Riess H, Leblond V, Oertel S; German PTLD Study Group and the European PTLD Network.
Trappe RU, et al. Among authors: leithauser m.
Am J Transplant. 2015 Apr;15(4):1091-100. doi: 10.1111/ajt.13086. Epub 2015 Mar 3.
Am J Transplant. 2015.
PMID: 25736912
Free article.